Maiwei (Shanghai) Biotechnology Co., Ltd
Initial public offering and listing on the science and Innovation Board
Issuance announcement
Sponsor (lead underwriter): Haitong Securities Company Limited(600837)
Scan QR code to view the full text of the announcement
Important tips
Maiwei (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as “Maiwei biotechnology”, “issuer” or “company”) in accordance with the implementation opinions on establishing a science and innovation board and pilot registration system in Shanghai Stock Exchange (CSRC announcement [2019] No. 2) issued by China Securities Regulatory Commission (hereinafter referred to as “CSRC” and “CSRC”) Measures for the administration of securities issuance and underwriting (CSRC order [No. 144]) (hereinafter referred to as the “administrative measures”), measures for the administration of the registration of initial public offering of shares on the science and Innovation Board (for Trial Implementation) (CSRC order [No. 174]), The implementation measures for the issuance and underwriting of shares on the science and Innovation Board of Shanghai Stock Exchange (SZF [2021] No. 76) (hereinafter referred to as the “implementation measures”) promulgated by Shanghai Stock Exchange (hereinafter referred to as “Shanghai Stock Exchange”) Guidelines for the application of the issuance and underwriting rules of the science and Innovation Board of Shanghai Stock Exchange No. 1 – initial public offering of shares (SZF [2021] No. 77) (hereinafter referred to as the “underwriting guidelines”), detailed rules for the implementation of online issuance of initial public offering of shares in Shanghai market (SZF [2018] No. 40) (hereinafter referred to as the “detailed rules for the implementation of online issuance”) Detailed rules for the implementation of offline issuance of initial public offerings in Shanghai market (SZF [2018] No. 41) (hereinafter referred to as “detailed rules for the implementation of offline issuance”), the code for underwriting initial public offerings under the registration system issued by the China Securities Association (zsxf [2021] No. 213) Rules for the administration of offline investors in initial public offering (zxsf [2018] No. 142), rules for the administration of offline investors in initial public offering under the registration system (zxsf [2021] No. 212) and other relevant provisions, as well as relevant rules on stock issuance and listing and the latest operation guidelines of Shanghai Stock Exchange, IPO and listing on the science and innovation board.
Haitong Securities Company Limited(600837) (hereinafter referred to as ” Haitong Securities Company Limited(600837) ” or “sponsor (lead underwriter)”) serves as the sponsor (lead underwriter) of this offering.
This offering is conducted by a combination of directional placement to strategic investors (hereinafter referred to as “strategic placement”), offline inquiry placement to qualified investors (hereinafter referred to as “offline issuance”), and online pricing issuance to social public investors holding non restricted A-Shares and non restricted depositary receipts market value in Shanghai market (hereinafter referred to as “online issuance”). The strategic placement, preliminary inquiry and online and offline issuance of this offering shall be organized and implemented by the sponsor (lead underwriter). The strategic placement of this offering is carried out at the sponsor (lead underwriter). The preliminary inquiry and offline subscription are carried out through the IPO offline subscription electronic platform of Shanghai Stock Exchange (hereinafter referred to as “offline subscription platform”), and the online offering is carried out through the trading system of Shanghai Stock Exchange. Please read this announcement carefully. For details of preliminary inquiry and electronic offline issuance, please refer to the website of Shanghai Stock Exchange (www.sse. Com.. CN.) The published rules for the implementation of offline issuance and other relevant provisions.
Investors can visit the following website（ http://www.sse.com..cn./disclosure/listedinfo/listing/ 、 http://www.sse.com..cn./ipo/home/ ）Check the full text of the announcement.
Basic information of the issuer
Full name of the company: Maiwei (Shanghai) biotechnology securities, hereinafter referred to as Maiwei biology
Technology Co., Ltd
Securities code / offline subscription 688062 online subscription code 787062
code
Offline subscription referred to as Maiwei biological online subscription referred to as Maiwei subscription
Basic information of this offering
Offline preliminary inquiry directly confirmed
The pricing method determines the issue price. The number of shares issued this time (10000 shares) is 9990.00 offline
Then conduct cumulative bid inquiry
The total share capital after issuance (10000 shares) is 39960.00, and the number of shares issued this time accounts for 25.00%
Proportion of total share capital after (%)
High price rejection ratio (%) 1.0156, whichever is lower (yuan / share) 34.0766
The issue price (yuan / whether the issue price exceeds the issue price of 34.8 yuan shares) is 34.80, the lower of the four numbers, and / share, the lower of the four numbers, and the excess range (%) is 2.12%
Issue price earnings ratio (earnings per share)
According to the issued Market Research rate in 2020 (per share)
The non recurring expenses deducted from the audit shall be calculated according to 2020
Inapplicability of attribution before and after profit and loss audited R & D expenses 23.92
The net profit of shareholders of the parent company divided by the total shares after the issuance
Divided by the total share capital after the issuance)
(this calculation)
Industry name and industry pharmaceutical manufacturing (C27) industry T-3 static 38.73
Code industry P / E ratio
532.3382 determined according to the issue price 5.33 determined according to the issue price
Commitment to subscribe for total strategic placement commitment to subscribe for total strategic placement
Proportion of (10000 shares) in the number of shares issued this time
（%）
Offline 7759.3618 after strategic placement callback online 1698.3000 after strategic placement callback
Number of shares issued (10000 shares)
Quantity of each proposed offline subscription
Upper limit (10000 shares) (3400 subscriptions, and the number of each proposed subscription offline is 100
The number shall be 100000 shares (10000 shares)
(several times) number of each proposed online subscription
Upper limit (10000 shares) (subscription of 1.65 new shares) placement brokerage fee of 0.5
The number shall be 500 shares, integer rate (%)
(Times) calculated according to the issuance price
The estimated total amount of raised funds is 347652.00, and the balance of underwriting method is underwriting
Amount (10000 yuan)
Important date of this issuance
Offline Subscription Date and start and end time January 4, 2022 online subscription date and start and end time January 4, 2022 between 9:30-15:00 and 9:30-11:30
13:00-15:00
Offline payment date and deadline January 6, 2022 online payment date and deadline January 6, 2022
Room 16:00
Remarks: 1 “The lower of the four numbers” refers to the lower of the median and weighted average of the remaining quotations of offline investors after excluding the highest quotation, as well as the median and weighted average of the remaining quotations of public products, social security funds and pensions.
The issuer and the recommendation institution (lead underwriter) solemnly remind investors to pay attention to investment risks and make rational investment, carefully read this announcement and publish it in Shanghai Securities News and China Securities News on December 31, 2021 (t-1) Special announcement on investment risk of Maiwei (Shanghai) Biotechnology Co., Ltd. in initial public offering and listing on the science and Innovation Board (hereinafter referred to as “special announcement on investment risk”) in the securities times and Securities Daily.
This announcement only briefly describes the issue of shares and does not constitute investment suggestions. Investors who want to know the details of this offering, please read it carefully and publish it on the website of Shanghai Stock Exchange on December 24, 2021 (www.sse. Com.. CN.) The letter of intent for the initial public offering and listing of Maiwei (Shanghai) Biotechnology Co., Ltd. on the science and Innovation Board (hereinafter referred to as the “letter of intent”). The issuer and the recommendation institution (lead underwriter) hereby remind investors to pay special attention to the chapters of “tips on major matters” and “risk factors” in the prospectus, fully understand the issuer’s risk factors, judge its operation status and investment value by themselves, and make investment decisions prudently. The issuer’s operating conditions may change due to the influence of politics, economy, industry and operation management level, and the possible investment risks shall be borne by the investors themselves.
The listing of the shares will be announced separately. 1、 Preliminary inquiry results and pricing
The application of Maiwei biology for the initial public offering of RMB common shares (A shares) and listing on the science and Innovation Board (hereinafter referred to as “this offering”) has been examined and approved by the stock listing committee of the science and Innovation Board of Shanghai Stock Exchange, and has been approved for registration by the CSRC (zjxk [2021] No. 3859). The issuer’s stock is referred to as “Maiwei biology” for short, and the extension is referred to as “Maiwei biology”, with the stock code of “688062”. This code is also used for the preliminary inquiry and offline subscription of this issuance, and the online subscription code of this issuance is “787062”.
The issuance is carried out in a combination of strategic placement, offline issuance and online issuance.
(i) Preliminary inquiry
1. Overall declaration
The initial inquiry period of this offering is 9:30-15:00 on December 29, 2021 (T-3). As of 15:00 on December 29, 2021 (T-3), the sponsor (lead underwriter) has received 9298 placing objects managed by 370 offline investors through the offline subscription platform of Shanghai Stock Exchange, with a quotation range of 7.15 yuan / share – 84.02 yuan / share, and the total number of proposed subscription is 167740300000 shares. For the specific quotation of the placing object, please refer to the “attached table: statistical table of investor quotation information” of this announcement.
2. Investor verification
According to the conditions for offline investors participating in the preliminary inquiry published in the announcement on the issuance arrangement and preliminary inquiry of Maiwei (Shanghai) Biotechnology Co., Ltd. for initial public offering and listing on the science and Innovation Board (hereinafter referred to as the “announcement on issuance arrangement and preliminary inquiry”) published on December 24, 2021, it has been verified by the sponsor (lead underwriter), 9 placing objects managed by 5 offline investors failed to provide audit materials or materials as required, but failed to pass the qualification audit of the sponsor (lead underwriter); 232 placing objects managed by 44 offline investors belong to the scope of prohibited placing; 13 placing objects managed by 6 offline investors failed to submit the pricing basis and recommended price or price range before the inquiry; The proposed subscription amount of one placing object managed by an offline investor exceeds the asset scale or capital scale in the filing materials submitted by it. The quotations of 255 placing objects managed by the above 55 offline investors have been determined to be invalid and eliminated, and the total number of shares to be purchased is 2772.4 million. For details, see the part marked as “invalid quotation” in the attached table “statistical table of investor quotation information”.
After excluding the above invalid quotations, the remaining 9043 placing objects managed by 359 offline investors meet the conditions of offline investors specified in the announcement on issuance arrangement and preliminary inquiry, with a quotation range of 7.15 yuan / share – 84.02 yuan / share, and the total number of shares to be purchased is 1649679.9 million.
（2） Excluding the highest quotation
1. Elimination
After the issuer and the recommendation institution (lead underwriter) rank the purchase price from high to low according to the inquiry results after excluding the above invalid quotation, and calculate the cumulative total amount of proposed purchase corresponding to each price, the proposed purchase quantity of the placing object at the same purchase price from small to large, and the same proposed purchase quantity at the same purchase price from late to early For the same proposed purchase price, the same proposed purchase quantity and the same purchase time (the purchase time shall be subject to the records of the offline purchase platform of Shanghai Stock Exchange), the placement objects automatically generated by the offline purchase platform of Shanghai Stock Exchange shall be sorted from back to front, and the proposed purchase shall be eliminated
